Nicanartine manufacturers
- Nicanartine
-
- $46.00
-
2026-05-06
- CAS:150443-71-3
- Purity: 99.64%
- Supply Ability: 10g
|
| | Nicanartine Basic information |
| Product Name: | Nicanartine | | Synonyms: | Nicanartine;2,6-di-tert-butyl-4-(3-(pyridin-3-ylmethoxy)propyl)phenol;Phenol, 2,6-bis(1,1-dimethylethyl)-4-[3-[(3-pyridinyl)methoxy]propyl]- | | CAS: | 150443-71-3 | | MF: | C23H33NO2 | | MW: | 355.51 | | EINECS: | | | Product Categories: | | | Mol File: | 150443-71-3.mol |  |
| | Nicanartine Chemical Properties |
| Boiling point | 442.3±45.0 °C(Predicted) | | density | 1.023±0.06 g/cm3(Predicted) | | pka | 12.52±0.40(Predicted) |
| | Nicanartine Usage And Synthesis |
| Uses | Nicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL). | | in vivo | Nicanartine inhibits smooth muscle cell proliferation after balloon catheter-induced endothelial injury and improves vascular reactivity as reflected by an increased response to acetylcholine-induced dilatation in cholesterol-fed and Watanabe rabbits[1]. | | References | [1] Hammes HP, et al. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia. 1997 Jun;40(6):629-34. DOI:10.1007/s001250050726
[2] H P Hammes, et al. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia. 1997 Jun;40(6):629-34. DOI:10.1007/s001250050726 |
| | Nicanartine Preparation Products And Raw materials |
|